Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ru Liu-Bryan

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Arthritis Research & Therapy|September 8, 2018
Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP-activated protein kinase (AMPK) signalingCharles McWherter, Yun-Jung Choi, Ramon L Serrano, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|March 17, 2024
The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic targetPaulo Gil Alabarse, Patricia Oliveira, Huaping Qin, et al.
Scientific Reports|October 19, 2024
Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulatorsConcepcion Sanchez, Anaamika Campeau, Ru Liu-Bryan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 12, 2013
Functional redundancy of MyD88-dependent signaling pathways in a murine model of histidyl-transfer RNA synthetase-induced myositisIrina Fernandez, Lisa Harlow, Yunjuan Zang, et al.
Research Square|May 20, 2024
Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement activation and inflammation modulatorsConcepcion Sanchez, Anaamika Campeau, Ru Liu-Bryan, et al.
Bioengineering & Translational Medicine|February 3, 2021
Cartilage-targeting ultrasmall lipid-polymer hybrid nanoparticles for the prevention of cartilage degradationXiangzhao Ai, Yaou Duan, Qiangzhe Zhang, et al.
Arthritis and Rheumatism|May 28, 2010
Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate crystal-induced inflammation in miceHal M Hoffman, Peter Scott, James L Mueller, et al.
Chemical Research in Toxicology|January 10, 2024
Synthesis, Detection, and Metabolism of Pyridone Ribosides, Products of NAD OveroxidationFaisal Hayat, J Trey Deason, Ru Liu Bryan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 19, 2019
Differential DNA Methylation of Networked Signaling, Transcriptional, Innate and Adaptive Immunity, and Osteoclastogenesis Genes and Pathways in GoutZengmiao Wang, Ying Zhao, Amanda Phipps-Green, et al.
Arthritis Research & Therapy|July 25, 2022
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytesMonica Guma, Benyamin Dadpey, Roxana Coras, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Arthritis Research & Therapy|September 8, 2018
Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP-activated protein kinase (AMPK) signalingCharles McWherter, Yun-Jung Choi, Ramon L Serrano, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|March 17, 2024
The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic targetPaulo Gil Alabarse, Patricia Oliveira, Huaping Qin, et al.
Scientific Reports|October 19, 2024
Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulatorsConcepcion Sanchez, Anaamika Campeau, Ru Liu-Bryan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 12, 2013
Functional redundancy of MyD88-dependent signaling pathways in a murine model of histidyl-transfer RNA synthetase-induced myositisIrina Fernandez, Lisa Harlow, Yunjuan Zang, et al.
Research Square|May 20, 2024
Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement activation and inflammation modulatorsConcepcion Sanchez, Anaamika Campeau, Ru Liu-Bryan, et al.
Bioengineering & Translational Medicine|February 3, 2021
Cartilage-targeting ultrasmall lipid-polymer hybrid nanoparticles for the prevention of cartilage degradationXiangzhao Ai, Yaou Duan, Qiangzhe Zhang, et al.
Arthritis and Rheumatism|May 28, 2010
Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate crystal-induced inflammation in miceHal M Hoffman, Peter Scott, James L Mueller, et al.
Chemical Research in Toxicology|January 10, 2024
Synthesis, Detection, and Metabolism of Pyridone Ribosides, Products of NAD OveroxidationFaisal Hayat, J Trey Deason, Ru Liu Bryan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 19, 2019
Differential DNA Methylation of Networked Signaling, Transcriptional, Innate and Adaptive Immunity, and Osteoclastogenesis Genes and Pathways in GoutZengmiao Wang, Ying Zhao, Amanda Phipps-Green, et al.
Arthritis Research & Therapy|July 25, 2022
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytesMonica Guma, Benyamin Dadpey, Roxana Coras, et al.
Pageof 5